HealthBioAI Announces the Acceptance by the Federal Drug Administration (FDA) to Proceed with a Randomized Clinical Trial for the Treatment of Long COVID/Post Acute Sequelae of COVID (PASC) with Selzentry® (maraviroc) in Combination with Lipitor (atorvastatin)

Posted on by

– New Company to support New Drug Application- HAYWARD, Calif., Feb. 15, 2024 /PRNewswire/ — HealthBioAI, a recently launched precision immunology company advancing new science for neglected immune-mediated diseases, today announced that the company’s clinical trial design to investigate…